12/15/23: Mowery lab published “Preclinical Evaluation of the ATR Inhibitor BAY 1895344 as a Radiosensitizer for Head and Neck Squamous Cell Carcinoma”

Mowery lab published “Preclinical Evaluation of the ATR Inhibitor BAY 1895344 as a Radiosensitizer for Head and Neck Squamous Cell Carcinoma” in the International Journal of Radiation Oncology*Biology*Physics.

These preclinical data supported the initiation of a multi-institutional phase I clinical trial evaluating the safety and efficacy of BAY 1895344 with radiation therapy and pembrolizumab in patients with recurrent, previously irradiated head and neck cancer.